Biofrontera Inc. (BFRIW) cash flow statement

BFRIWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRI

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30

$0.00+0.00 (0.00%)

Close on Oct 30, 2026Market cap $12.96MP/E –Yield –

Biofrontera Inc. cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Depreciation & Amortization	0.14	0.42	0.60	–	–	–
Stock-Based Compensation	0.95	1.02	1.05	1.85	0.13	–
Change in Accounts Receivable	-1.91	-0.32	-1.54	-0.07	-0.61	1.17
Change in Inventory	1.45	4.23	-3.75	-2.81	2.59	-0.27
Change in Accounts Payable	0.61	-0.23	-6.35	-3.61	–	–
Operating Cash Flow	-13	-10	-25	-16	-27	-12
Capital Expenditures	0.00	-0.01	-0.01	-0.04	–	–
Purchase of Investments	–	–	–	-5.12	–	–
Sale & Maturity of Investments	–	0.06	0.62	–	–	–
Investing Cash Flow	3.00	0.00	0.62	-5.16	-0.01	–
Stock Issued	–	–	4.51	–	15	–
Financing Cash Flow	11	15	8.41	14	43	13
Net Change in Cash	0.49	4.56	-16	-7.33	16	0.83
Free Cash Flow	-13	-10	-25	-16	–	–
Income Taxes Paid	0.03	0.02	0.02	0.03	0.06	0.06
Interest Paid	0.01	1.73	0.13	0.00	0.00	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -14.2%
Net margin: -13.8%
Return on equity, FY2025: -141.3%

Financial strength

Current ratio: 1.18
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 44.2%

Valuation

P/E ratio: –
Price to sales: 0.28
Price to book: 2.18
Dividend yield: –